Rona Therapeutics Announces Breakthrough Preclinical Data for Long-Acting RNAi Therapy RN026 Targeting Lipoprotein(a)

Jun 03, 2025 09:58 CST Updated 09:58

Rona Therapeutics

Nucleic Acid Drug Developer

｜Edited by the Content Team of Zhong肽 Biochemical

Recently，Rona Therapeutics, a leader in innovative RNA therapies, announced preclinical data for its self-developed innovative RNA interference therapy, RN026, at the National Lipid Association's 2025 Annual Scientific Sessions held on May 29 local time. Preclinical studies showed that the therapy targets lipoprotein(a) (Lp(a)), an independent risk factor for cardiovascular diseases, achieving a 99% reduction in non-human primate (NHP) studies.The reduction in Lp(a) levels andExpected to support an annual dosing regimen.

Preclinical studies have shown,This therapy targets cardiovascular diseases.Independent Risk Factor Lipoprotein (a)（Lp(a)）, in non-human primates（NHP）The study achieved a 99% reduction in Lp(a) levels and is expected to support an annual dosing regimen.

Potent and Long-lasting, Breakthrough Efficacy

In transgenic mouse models, a single 2mg/kg subcutaneous injection can achieve: a 98% reduction in serum apolipoprotein Apo(a) levels, with efficacy lasting at least 42 days.
In non-human primate (NHP) studies, serum Lp(a) was reduced by up to 99%; 95% of Lp(a) inhibition was maintained 98 days after dosing, and the effect of approximately 80% reduction in serum Lp(a) levels persisted until day 154, suggesting the potential for once-yearly dosing.OneSubsequent AdministrationMedicine

Precision Targeted Design

Targeting Multiple Sites Inside and Outside the KIV-2 CNV Region for Robust Efficacy
Greatly reduce the possibility of sequence-related off-target effects

Dual Benefits

In NHP studies, a 25% reduction in low-density lipoprotein cholesterol (LDL-C) levels was observed.
No Observed Toxicity in SD Rats Repeat Dose Study

About RN026

RN026 Shows Great Potential as a Breakthrough Therapy in Cardiovascular Disease Areas Such as Atherosclerotic Cardiovascular Disease (ASCVD), Aortic Stenosis, and Peripheral Artery Disease, with Significant Advantages in Differentiated Long-Acting Properties, Potent Lp(a) Inhibition Capability, and Excellent Safety. Approximately 10%-20% of the Global Population Has Elevated Lipoprotein(a) Levels, and RN026 is Expected to Bring New Hope for Cardiovascular Disease Patients.

About Rona Therapeutics

Rona Therapeutics is a global leading nucleic acid innovative drug platform company. Relying on its self-developed nucleic acid chemistry and delivery platform, it focuses on the treatment of cardiometabolic diseases, obesity, and neurological disorders. Rona Therapeutics is committed to developing best-in-class and first-in-class siRNA drugs with differentiation and innovation to address the treatment of cardiovascular diseases, obesity, and metabolic dysfunction-associated steatohepatitis (MASH).

Source:

1.Rona Therapeutics